Your session is about to expire
← Back to Search
Nitric Oxide Synthase Inhibitor
Phenylephrine for Vasovagal Syncope
Phase < 1
Waitlist Available
Led By Julian M. Stewart, M.D., Ph.D.
Research Sponsored by New York Medical College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
This trial will study the effects of a simple molecule, nitric oxide, on people with vasovagal syncope (simple postural faint) or postural tachycardia syndrome (POTS).
Eligible Conditions
- Vasovagal Syncope
- Postural Orthostatic Tachycardia Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Heart rate and blood pressure in response to Lower Body Negative Pressure(LBNP)
Secondary outcome measures
Adrenergic neurotransmission as measured by Muscle Sympathetic Nerve Activity(MSNA), doppler ultrasound blood flow, venous Norepinephrine in response to Phenylephrine infusion
Trial Design
1Treatment groups
Experimental Treatment
Group I: Phenylephrine and L-Ng-monomethyl Arginine (L-NMMA)Experimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Phenylephrine
2014
Completed Phase 4
~2050
Find a Location
Who is running the clinical trial?
New York Medical CollegeLead Sponsor
69 Previous Clinical Trials
5,971 Total Patients Enrolled
1 Trials studying Vasovagal Syncope
30 Patients Enrolled for Vasovagal Syncope
Julian M. Stewart, M.D., Ph.D.Principal InvestigatorNew York Medical College
1 Previous Clinical Trials
51 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger